---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000086"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:40:00.583496+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025

## Summary
- ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.
- ORR 84.2% in WM (n=19 evaluable); included 10.5% VGPR, 57.9% PR; IgM reductions >90% in three patients.
- Well tolerated across 50-600 mg doses; common AEs low-grade purpura/contusion (45.8%), neutropenia (29.2%); no new atrial fibrillation.
- Patients heavily pretreated: median 4 prior lines, 97.9% prior BTKi, 83.3% prior BCL2i; responses seen regardless of baseline mutations or CNS involvement.
- Nurix on track to initiate pivotal trials of bexobrutideg in 2025.

## SEC filing metadata
- accession: 0001549595-25-000086
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000086/0001549595-25-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000086/nrix-20250612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000086
- JSON: https://secwatch.observer/filing/0001549595-25-000086.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.